News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
540,782 Results
Type
Article (39557)
Company Profile (120)
Press Release (501105)
Section
Business (154081)
Career Advice (2430)
Deals (28036)
Drug Delivery (89)
Drug Development (73072)
Employer Resources (141)
FDA (13597)
Job Trends (12256)
News (274085)
Policy (27160)
Tag
Academia (2541)
Alliances (38890)
Alzheimer's disease (1245)
Approvals (13521)
Artificial intelligence (115)
Bankruptcy (303)
Best Places to Work (9926)
Biotechnology (95)
Breast cancer (112)
Cancer (981)
Cardiovascular disease (90)
Career advice (2041)
Cell therapy (206)
Clinical research (57993)
Collaboration (322)
Compensation (109)
COVID-19 (2428)
C-suite (97)
Data (999)
Diabetes (139)
Diagnostics (5564)
Earnings (54253)
Employer resources (129)
Events (74532)
Executive appointments (274)
FDA (14060)
Funding (303)
Gene therapy (164)
GLP-1 (565)
Government (4063)
Healthcare (16033)
Infectious disease (2511)
Inflammatory bowel disease (97)
Interviews (522)
IPO (12550)
Job creations (2635)
Job search strategy (1680)
Layoffs (375)
Legal (5747)
Lung cancer (170)
Manufacturing (145)
Medical device (10470)
Medtech (10474)
Mergers & acquisitions (15530)
Metabolic disorders (376)
Neuroscience (1510)
NextGen Class of 2024 (5558)
Non-profit (4002)
Northern California (1234)
Obesity (210)
Opinion (187)
Patents (97)
People (50244)
Phase I (17809)
Phase II (25510)
Phase III (19476)
Pipeline (429)
Postmarket research (2313)
Preclinical (7322)
Radiopharmaceuticals (203)
Rare diseases (193)
Real estate (4209)
Regulatory (18540)
Research institute (2128)
Resumes & cover letters (358)
Southern California (1110)
Startups (2826)
United States (10733)
Vaccines (505)
Weight loss (164)
Date
Last 7 days (822)
Last 30 days (2984)
Last 365 days (30918)
2024 (27999)
2023 (34582)
2022 (45117)
2021 (48437)
2020 (46822)
2019 (39964)
2018 (30295)
2017 (27280)
2016 (26035)
2015 (30341)
2014 (22852)
2013 (18612)
2012 (20017)
2011 (20966)
2010 (18561)
Location
Africa (730)
Arizona (118)
Asia (33271)
Australia (6959)
California (2723)
Canada (1113)
China (208)
Colorado (118)
Connecticut (111)
Europe (74088)
Florida (389)
Georgia (88)
Illinois (284)
Indiana (173)
Kansas (87)
Maryland (500)
Massachusetts (1902)
Michigan (136)
Minnesota (200)
New Jersey (773)
New York (781)
North Carolina (579)
Northern California (1234)
Ohio (115)
Pennsylvania (644)
South America (997)
Southern California (1110)
Texas (367)
Utah (80)
Washington State (296)
540,782 Results for "celyad formally known as cardio3 biosciences".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Celyad Oncology announces intention to terminate SEC reporting obligations
Celyad Oncology SA announces that it will voluntarily file a Form 15F with the United States Securities and Exchange Commission to terminate its SEC reporting obligations under Section 13 or Section 15 of the Securities Exchange Act of 1934, as amended.
February 8, 2024
·
4 min read
Business
Celyad Oncology provides fourth quarter 2023 business update and 2024 outlook
Celyad Oncology (Euronext: CYAD) (the “Company”), today provides a fourth quarter 2023 business update and an outlook for 2024.
January 16, 2024
·
7 min read
Drug Development
Saghmos Therapeutics Announces Collaboration with Duke Clinical Research Institute to Optimize Phase 3 Cardio-Renal Metabolic Study
Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company, announced it will partner with the Duke Clinical Research Institute (DCRI) to optimize all aspects of and plan the operationalization of Saghmos’ Phase 3 study for its cardio-renal metabolic modulator ST-62516.
April 17, 2024
·
4 min read
Business
Celyad announces management change - December 04, 2023
Celyad Oncology announces that its CEO and managing director Georges Rawadi has decided to step down, effective as of Friday December 1, 2023.
December 4, 2023
·
3 min read
Business
Celyad Oncology reports third quarter 2023 financial results and recent business highlights
Celyad Oncology, a biotechnology company focused on innovative technologies for chimeric antigen receptor T-cell therapies, reports its financial results for the third quarter of 2023 and provides an update on recent business developments.
November 9, 2023
·
9 min read
Celyad Oncology announces the termination of its American Depository Receipt program
Celyad Oncology SA announces that Citibank, N.A., as depositary, shall issue the notice of terminating its American Depository Receipt program of American Depositary Shares representing ordinary shares to the holders of ADSs according to the requirements under the deposit agreement.
September 25, 2023
·
4 min read
BioMidwest
New Cohort Study Data Shows Baxter’s Expanded Hemodialysis – Known as HDx Therapy – Is Associated With Approximately 25% Lower Mortality Rate for up to Four Years
Baxter International Inc. announced new data showing expanded hemodialysis, known as HDx therapy, enabled by Theranova dialyzer, was associated with an approximately 25% lower all-cause mortality risk for up to four years when compared to high-flux hemodialysis.
May 29, 2024
·
5 min read
Celyad Oncology Reports First Half 2023 Financial Results and Recent Business Highlights
Celyad Oncology, announces its financial results and recent business developments for the first half year, ended June 30, 2023.
September 4, 2023
·
14 min read
Policy
Celyad Oncology announces receipt of Nasdaq delisting notice
Celyad Oncology, is a biotechnology company focused on innovative technologies for chimeric antigen receptor T-cell therapies.
May 15, 2023
·
5 min read
Drug Development
Genetesis Formally Launches MICRO2 Trial with Announcement of First Patient Enrollment
July 3, 2024
·
4 min read
1 of 54,079
Next
